Ultrafast, Single B Cell-based Anti-idiotypic mAb Discovery Against a mAb Therapeutic
Case study showcasing Delivery of PK assay-ready mAbs in 11 weeks to meet aggressive clinical timelines.
Identifying specific mAb binders to a CAR, enabling drug quantification in patient serum sample. Partner required a diverse panel of anti-idiotypic mAbs against the antigenic determinant of ‘CAR-T X’ to support functional measurements in an upcoming clinical trial.
Covered in this Case Study